Skip to main content

Table 4 Neurologic adverse reactions of thalidomide and bortezomib in relation to phenotype in CYP2C19 C and CYP2D6

From: No influence of the polymorphisms CYP2C19 and CYP2D6 on the efficacy of cyclophosphamide, thalidomide, and bortezomib in patients with Multiple Myeloma

Parameter CYP2C19
EM
(%)
CYP2C19
IM + PM (%)
P value CYP2D6
UM + EM
(%)
CYP2D6
IM + PM
(%)
p value
Thalidomide       
Grade 0 + 1 64 (51) 21 (52) 0.6 NR NR 0.7
Grade 2 36 (29) 5 (13)     
Grade 3 26 (21) 14 (35)     
Bortezomib       
Grade 0 + 1 22 (46) 8 (50) 0.7 14 (54) 8 (42) 0.5
Grade 2 11 (23) 4 (25)   7 (27) 6 (32)  
Grade 3 15 (31) 4 (25)   5 (19) 5 (26)  
  1. NR: not relevant